Johnson & Johnson $JNJ Shares Sold by Laffer Tengler Investments Inc.

Laffer Tengler Investments Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 13.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 43,400 shares of the company’s stock after selling 7,015 shares during the period. Johnson & Johnson accounts for about 1.3% of Laffer Tengler Investments Inc.’s portfolio, making the stock its 25th largest holding. Laffer Tengler Investments Inc.’s holdings in Johnson & Johnson were worth $8,047,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. SOA Wealth Advisors LLC. increased its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after purchasing an additional 53 shares during the last quarter. Ethos Financial Group LLC boosted its stake in Johnson & Johnson by 0.6% during the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after buying an additional 53 shares during the period. Pinnacle Holdings LLC increased its position in shares of Johnson & Johnson by 0.5% during the third quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock valued at $2,079,000 after acquiring an additional 54 shares during the last quarter. Heritage Oak Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 3.5% in the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after acquiring an additional 55 shares during the period. Finally, Investor s Fiduciary Advisor Network LLC lifted its holdings in shares of Johnson & Johnson by 0.8% in the 3rd quarter. Investor s Fiduciary Advisor Network LLC now owns 6,905 shares of the company’s stock worth $1,280,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Leerink Partners raised their price target on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research report on Thursday, January 22nd. Rothschild & Co Redburn boosted their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a “neutral” rating in a report on Thursday, February 19th. Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, HSBC lifted their target price on Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $232.70.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $246.77 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market cap of $594.69 billion, a price-to-earnings ratio of 22.33, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. The stock’s 50-day moving average is $226.32 and its two-hundred day moving average is $203.01. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is 47.06%.

Insiders Place Their Bets

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus (SLE) — designation follows positive Phase 2 data and a Phase 3 enrollment; this can speed review and raises the commercial potential of a new immunology asset. PR Newswire
• Positive Sentiment: Drug pipeline momentum: J&J reported encouraging early results for oncology candidate pasritamig and is preparing Phase 3 plans; continued progress across immunology and neuroscience (Tremfya, Caplyta, Spravato) is offsetting some revenue headwinds. Yahoo Finance
• Positive Sentiment: Market context: broader Dow strength is supporting JNJ’s move higher today as large-cap pharma recovers, giving momentum to shares. Kalkine Media
• Neutral Sentiment: Investor events and cadence: J&J scheduled an investor conference call for April 14 to review Q1 results — a routine event that could provide guidance/clarity but is not immediate catalyst. Business Wire
• Neutral Sentiment: Income appeal: J&J appears on several March dividend-stock lists, reinforcing steady-income investor interest but offering limited short-term price impact. Blockonomi
• Neutral Sentiment: Conference presentation material (TD Cowen transcript) gives investors detail on strategy and pipeline execution; useful for longer-term thesis but not an immediate mover. Seeking Alpha
• Negative Sentiment: Bayer legal action: Bayer has initiated a legal challenge related to prostate-cancer product claims — this creates regulatory and litigation risk that could weigh on sentiment and add to uncertainty. Yahoo Finance
• Negative Sentiment: Analyst stance: some sell-side notes (Bank of America reiteration/Hold) point to limited near-term upside despite better oncology estimates — tempers rally expectations. TipRanks

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.